Abcam, ab266103, Human USP33 knockout HEK-293T cell line

Size: 2 x 1000000Cells / vial / 1000000Cells / vial
USP33 KO cell line available to order. KO validated by. Free of charge wild type control available. Knockout achieved by using CRISPR/Cas9, Homozygous: 1 bp insertion in exon 5. To order both knockout and wild-type control cells: select 2 x 1000000Cells/vial. To order only knockout cells: select 1000000Cells/vial.
Key facts
Cell type:HEK-293T,
Species or organism:Human,
Tissue:Kidney,
Form:LiquidSee storage information,
Knockout validation:Sanger Sequencing,
Mutation description:Knockout achieved by using CRISPR/Cas9, Homozygous: 1 bp insertion in exon 5

Product details:
We will provide viable cells that proliferate on revival.
This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our
limited use license
patent pages

Properties and Storage Information:
Gene name-USP33, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Zygosity-Homozygous, Shipped at conditions-Dry Ice, Appropriate short-term storage conditions--196°C, Appropriate long-term storage conditions--196°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
USP33 also known as ubiquitin-specific peptidase 33 is an important enzyme involved in the ubiquitin-proteasome system. It has a molecular mass of about 105 kDa. USP33 acts as a deubiquitinating enzyme meaning it removes ubiquitin from target proteins which stabilizes or changes their function. You find USP33 expressed in various tissues with significant levels in the brain lung and heart. Alternate names include VDU1 and a few other names reflecting variations in biological contexts.
Biological function summary
USP33 plays roles in cellular processes like signal transduction and intracellular trafficking often as part of protein complexes. Its enzymatic activity influences the regulation of proteins tasked with moving cellular components cytoskeletal dynamics and response to hypoxia. Acting on proteins such as beta-arrestin2 USP33 influences the endocytosis and recycling of G-protein-coupled receptors (GPCRs). This role allows it to impact multiple receptor-mediated signaling pathways.
Pathways
USP33 participates in critical cellular pathways including the hypoxia response and Wnt signaling. It interacts with hypoxia-inducible factor 1-alpha (HIF-1α) modifying its stability and affecting cellular response to low oxygen levels. In the Wnt signaling pathway it modulates the activity of beta-catenin through deubiquitination which is essential for cell proliferation and differentiation. These roles highlight USP33's position within wide networks of cellular regulation influencing different proteomic interactions and outcomes.
USP33 has been linked to certain cancers and neurodegenerative diseases. Its interaction with HIF-1α connects it to tumor progression as altered USP33 expression can influence cancer cell survival in hypoxic conditions. In neurodegenerative diseases like Parkinson's changes in the deubiquitination activity of USP33 may lead to protein aggregation. Its interactions with proteins such as alpha-synuclein are relevant as these proteins play a significant role in disease pathology. Understanding USP33's functions and associations offers insight into potential therapeutic targets.